Bard Seeks $67M Damages Award In Vascular Port IP Case

Law360, Wilmington (March 4, 2019, 9:03 PM EST) -- A subsidiary of medical device maker C.R. Bard Inc. told a Delaware federal jury Monday that it is owed $67.5 million in damages from competitor AngioDynamics Inc. for its infringement of three patents related to fluid injection port technology.

During opening arguments in the trial, Bard Peripheral Vascular Inc. attorney Vincent J. Belusko of Morrison & Foerster LLP said AngioDynamics was fully aware of Bard’s patents for power port technology when it began selling its Smart Port and BioFlo devices, and that Bard is entitled to a reasonable royalty for the indirect infringement allegedly committed by AngioDynamics.

The three patents-in-suit deal...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!